🎉 M&A multiples are live!
Check it out!

OKYO Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for OKYO Pharma and similar public comparables like Benevolent AI, Pharming, and Vivoryon Therapeutics.

OKYO Pharma Overview

About OKYO Pharma

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.


Founded

2007

HQ

United States of America
Employees

3

Website

okyopharma.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$35.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

OKYO Pharma Financials

OKYO Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, OKYO Pharma achieved revenue of n/a and an EBITDA of -$15.7M.

OKYO Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See OKYO Pharma valuation multiples based on analyst estimates

OKYO Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$13.2M -$15.7M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$5.4M -$13.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

OKYO Pharma Stock Performance

As of April 15, 2025, OKYO Pharma's stock price is $1.

OKYO Pharma has current market cap of $36.8M, and EV of $35.8M.

See OKYO Pharma trading valuation data

OKYO Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$35.8M $36.8M XXX XXX XXX XXX $-0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

OKYO Pharma Valuation Multiples

As of April 15, 2025, OKYO Pharma has market cap of $36.8M and EV of $35.8M.

OKYO Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate OKYO Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for OKYO Pharma and 10K+ public comps

OKYO Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $35.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -4.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get OKYO Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

OKYO Pharma Valuation Multiples

OKYO Pharma's NTM/LTM revenue growth is n/a

OKYO Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $5.2M for the same period.

Over next 12 months, OKYO Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate OKYO Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for OKYO Pharma and other 10K+ public comps

OKYO Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $5.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

OKYO Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

OKYO Pharma M&A and Investment Activity

OKYO Pharma acquired  XXX companies to date.

Last acquisition by OKYO Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . OKYO Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by OKYO Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About OKYO Pharma

When was OKYO Pharma founded? OKYO Pharma was founded in 2007.
Where is OKYO Pharma headquartered? OKYO Pharma is headquartered in United States of America.
How many employees does OKYO Pharma have? As of today, OKYO Pharma has 3 employees.
Who is the CEO of OKYO Pharma? OKYO Pharma's CEO is Dr. Gary S. Jacob, PhD.
Is OKYO Pharma publicy listed? Yes, OKYO Pharma is a public company listed on NAS.
What is the stock symbol of OKYO Pharma? OKYO Pharma trades under OKYO ticker.
When did OKYO Pharma go public? OKYO Pharma went public in 2022.
Who are competitors of OKYO Pharma? Similar companies to OKYO Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of OKYO Pharma? OKYO Pharma's current market cap is $36.8M
Is OKYO Pharma profitable? Yes, OKYO Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.